All In Biotech

Drug Trial Radar · NCT04648254

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 With a Cohort Expansion at the RP2D in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Nov 18, 2020

Primary completion

Dec 23, 2025

Study completion Dec 23, 2025

Sponsor

Lead sponsor
Qurient Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.

Conditions

  • Solid Tumor
  • Advanced Cancer
  • Metastatic Cancer

Interventions

  • Q702Drug

    The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702Time frame: 28 days of cycle 1

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Northwestern University

    Chicago, Illinois

  • Atlantic Health System Hospital

    Morristown, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.